Evidence map›Paper›PMID 32440915›Full record

ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2020

Latest progress in molecular biology and treatment in genitourinary tumours.

A González-Del-Alba, J Á Arranz, J Bellmunt, J P Maroto, O Fernández-Calvo, B P Valderrama, E González-Billalabeitia, M J Méndez-Vidal, J Cassinello, N Romero-Laorden and 6 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 15 institutions in 2 countries.

A González-Del-AlbaMedical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.
J Á ArranzMedical Oncology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain.
J BellmuntMedical Oncology Department, Dana-Farber Cancer Institute, Boston, USA.
J P MarotoMedical Oncology Department, Hospital Universitari Santa Creu i Sant Pau, Barcelona, Spain.
O Fernández-CalvoMedical Oncology Department, Complexo Hospitalario Universitario de Ourense, Orense, Spain.
B P ValderramaMedical Oncology Department, Hospital Univeristario Virgen del Rocío, Sevilla, Spain.
E González-BillalabeitiaMedical Oncology Department, Hospital Universitario Morales Meseguer, Murcia, Spain.
M J Méndez-VidalMedical Oncology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.
J CassinelloMedical Oncology Department, Hospital Universitario de Guadalajara, Guadalajara, Spain.
N Romero-LaordenMedical Oncology Department, Hospital Universitario La Princesa, Madrid, Spain.
M Á ClimentMedical Oncology Department, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
J PuenteMedical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain.
I PeláezMedical Oncology Department, Hospital Universitario de Cabueñes, Gijón, Spain.
M Lázaro-QuintelaMedical Oncology Department, Hospital Universitario Alvaro Cunqueiro, Vigo, Spain.
E GallardoMedical Oncology Department, Hospital Univeristari Parc Tauli, Institut d'Investigació I Innovació Parc Taulí I3PT. Universidad Autonoma de Barcelona, Sabadell, Spain.
C SuárezMedical Oncology Department, Hospital Universitari Vall d'Hebron, Institute of Oncology, Universidad Autònoma de Barcelona, Barcelona, Spain. csuarez@vhio.net.ORCID http://orcid.org/0000-0002-0502-5528
Universitat Autònoma de Barcelona · ESComplexo Hospitalario Universitario A Coruña · ESDana-Farber Cancer Institute · USFundación Instituto Valenciano de Oncología · ESHospital de Sant Pau · ESHospital General Universitario Gregorio Marañón · ESHospital General Universitario Morales Meseguer · ESHospital Universitario De Cabueñes · ESHospital Universitario de Guadalajara · ESHospital Universitario de La Princesa · ESHospital Universitario Puerta de Hierro Majadahonda · ESHospital Universitario Reina Sofía · ESHospital Universitario Virgen del Rocío · ESInstituto de Investigación Sanitaria del Hospital Clínico San Carlos · ESUniversity Hospital Complex Of Vigo · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The management of genitourinary cancer, including bladder, prostate, renal and testicular cancer, has evolved dramatically in recent years due to a better understanding of tumour genetic mutations, alterations in molecular pathways, and to the development of new kinds of drugs such as targeted therapies and immunotherapies. In the field of immunotherapy, new drugs focused on stimulating, enhancing and modulating the immune system to detect and destroy cancer, have been recently discovered. Research in oncology moves quickly and new data of great relevance for clinical practice are communicated every year. For this reason, a group of experts, focused exclusively on the treatment of genitourinary tumours and who get together every year in the BestGU conference to assess the latest progress in this field have summarized the most important advances in a single review, along with a critical assessment of whether these results should alter daily clinical practice.

Indexed as

Antineoplastic AgentsClinical Trials as TopicCystectomyDrugs, InvestigationalFemaleHumansImmunotherapyKidney NeoplasmsMaleMolecular Targeted TherapyMutationNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasms, Germ Cell and EmbryonalNephrectomyProstatic NeoplasmsAntineoplastic AgentsDrugs, InvestigationalBladder cancerProstate cancerRenal cancerTesticular cancerUrogenital malignancies

Identifiers

PMID32440915
OpenAlexW3027537426

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.